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UtThe Cardiometabolic Think Tank was convened on June 20, 2014, in Washington, DC, as a “call to action” activity focused
on deﬁning new patient care models and approaches to address contemporary issues of cardiometabolic risk and disease.
Individual experts representing >20 professional organizations participated in this roundtable discussion. The Think Tank
consensus was that the metabolic syndrome (MetS) is a complex pathophysiological state comprised of a cluster of
clinically measured and typically unmeasured risk factors, is progressive in its course, and is associated with serious and
extensive comorbidity, but tends to be clinically under-recognized. The ideal patient care model for MetS must accurately
identify those at risk before MetS develops and must recognize subtypes and stages of MetS to more effectively direct
prevention and therapies. This new MetS care model introduces both afﬁrmed and emerging concepts that will require
consensus development, validation, and optimization in the future. (J Am Coll Cardiol 2015;66:1050–67) © 2015 by the
American College of Cardiology Foundation.EXECUTIVE SUMMARY
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AB BR E V I A T I O N S
AND ACRONYM S
ACC = American College of
Cardiology
ACO = accountable care
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PCMH = patient-centered
medical home
T2D = type 2 diabetes
TT = think tank
VAT = visceral adipose tissue
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1051have sufﬁcient potential beneﬁt to warrant actionable
recommendations.
AC.1. Metabolic syndrome (MetS) is a progressive
pathophysiological state associated with sub-
stantially increased risk for development of type
2 diabetes (T2D) and atherosclerotic cardiovas-
cular disease (ASCVD).
AC.2. MetS is clinically manifested by a cluster of risk
factors that are causally inter-related (not
aggregating by chance alone).
AC.3. Risk for adverse health outcomes increases sub-
stantially with accumulation of componentMetS
risk factors, in addition to unmeasured (“resid-
ual risk”) factors. Timely recognition ofMetS risk
factors helps to identify individuals at high risk
for ASCVD and T2D and to initiate preventive
strategies before end-organ damage occurs.
AC.4. Obesity is a MetS risk factor that is imperfectly
gauged by body mass index and/or waist
circumference, and is modulated by adipocyte
distribution, size, and function, as well as race,
behavior, and lifestyle. Excess ectopic and/or
visceral adiposity is fundamental to the path-
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1052EC.1. MetS should be classiﬁed by subtype and
stage, which translate to speciﬁc evidence-
based management algorithms to improve clin-
ical outcomes.
EC.2. Improved metrics to deﬁne high-risk obesity
are needed and may be characterized by
evidence-based assessments including, but not
limited to, waist circumference, body com-
position, and imaging-based assessments of
ectopic fat and/or visceral adipose tissue.
EC.3. Structured lifestyle interventions for residual
risk reduction are required. Focused research
and improved education on lifestyle medicine
are also needed.
EC.4. Health care disparities need to be addressed
with respect to: 1) access to structured lifestyle
interventions; 2) integrated care delivery sys-
tems with enhanced provider awareness,
accountability, and communication, along with
tools to appropriately identify and treat those
at risk; and 3) community engagement.
EC.5. New care models, such as the patient-centered
medical home (PCMH) and Accountable Care
Organizations (ACOs), are needed that incor-
porate new technology, electronic health re-
cords, and novel reimbursement paradigms.
KEY FINDINGS. After reviewing the afﬁrmed and
emergent concepts, the writing committee formu-
lated 5 key ﬁndings (KFs).
KF.1. MetS is a cluster of risk factors, both formally
deﬁned and less well recognized, that increase
the risk of certain diseases.
KF.2. The presence of ectopic fat and/or visceral
adipose tissue is critical to the pathogenesis of
MetS and may explain some of the variability in
phenotypic presentation across racial groups.
KF.3. A new care model for patients with MetS is
essential and should include screening, risk
stratiﬁcation, and algorithmic management of
patients according to the speciﬁc subtype and
stage.
KF.4. Structured lifestyle interventions are required
to adequately treat MetS and reduce residual
ASCVD risk.
KF.5. Implementation of a new patient care model
should focus on integrated care delivery,
alternative reimbursement strategies (perhaps
utilizing the emerging constructs of the PCMH
and ACO), and education that uses structured
lifestyle intervention; optimal use of pharma-
ceuticals, including combination therapies; and
appropriate consideration of surgery.INTRODUCTION
MetS recognizes a group of risk factors underlying
cardiovascular and metabolic disease. The most
accepted clinical deﬁnition, established by the
National Cholesterol Education Program’s Adult
Treatment Panel III (NCEP-ATP III) in 2001, recognizes
multiple components of the syndrome related to
atherosclerotic cardiovascular disease (ASCVD) risk:
abdominal obesity, atherogenic dyslipidemia, ele-
vated blood pressure, insulin resistance with or
without glucose intolerance, proinﬂammatory state,
and prothrombotic state. The criteria for clinical diag-
nosis of MetS are 3 or more of the following: 1) waist
circumference>102 cm (40 in) inmen and 88 cm (35 in)
in women; 2) triglycerides$150 mg/dl; 3) high-density
lipoprotein cholesterol (HDL-C) <40 mg/dl in men
and <50 mg/dl in women; 4) blood pressure $130/85
mm Hg; and 5) fasting glucose $100 mg/dl (1). In 2005,
the NCEP-ATP III criteria were modiﬁed to suggest
lower waist circumference cutpoints for Asian Ameri-
cans ($90 cm [35 inches] inmen and$80 cm [31 inches]
in women) (2). However, these criteria do not fully
encompass the pathophysiological complexity of the
syndrome, recognize predisposition to different types
of end-organ damage, or account for health disparities
according to race, sex, or socioeconomic status, in
screening for or treating the syndrome.
MetS is typically under-recognized in the clinical
setting, even just on the basis of the 5 standard
criteria. Additional elements of MetS include high
apolipoprotein B, small low-density lipoprotein (LDL)
particle size, endothelial dysfunction, insulin resis-
tance, and prothrombotic and proinﬂammatory
states. Not only are these less widely appreciated as
components of MetS, but they are also not typically
measured in a clinical setting. MetS consists of ele-
ments that do not aggregate by chance alone and are
causally inter-related, and each element contributes
independently to an increased risk for ASCVD (3).
Factor analysis in epidemiological studies in different
populations, including adolescents and ethnic
minorities, demonstrates clustering of risk in the do-
mains of adiposity and/or dyslipidemia, hypergly-
cemia or insulin resistance, and hypertension that
explain 37% to 70% of variation and vary by sex and
race (4–7). For example, Malay women with MetS had
different factor patterns with greater importance of
hypertension, insulin resistance, and triglycerides
when compared with other South Asian women (7).
These ﬁndings highlight the racial phenotypic vari-
ability of MetS that is not well captured by standard
MetS paradigms.
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number of MetS elements increases. In the Hoorn
study in the Netherlands, the risk of cardiovascular
outcomes rose rapidly with an increasing number of
MetS components, becoming statistically signiﬁcant
at $3 factors for men and $2 factors for women (8).
Other studies have demonstrated that MetS com-
pounds the risk for ASCVD when other known risk
factors, such as T2D, are present. A meta-analysis,
including 87 studies with 951,083 patients, demon-
strated that MetS was associated with a >2-fold
increased risk for ASCVD and cardiovascular mor-
tality (9). MetS is present in w50% of patients with
diagnosed vascular disease and may be even more
prevalent among women with ASCVD (10,11). In the
Framingham Offspring Study, both MetS and T2D
increased the risk of stroke by approximately 2-fold,
and those patients with both had an even higher risk
(12). ASCVD risk is higher with MetS in the absence
of T2D compared with T2D without MetS (13.9% vs.
7.5%, respectively) (13).
The prevalence of MetS increases dramatically with
increasing obesity. In men in the NHANES (National
Health and Nutrition Examination Survey) from 2003
to 2006, MetS was present in 6.8% of normal weight,
29.8 % of overweight, and 65% of obese individuals
(14). Similarly, among women, 9.3% of normal weight,
33.1% of overweight, and 56.1% of obese individuals
had MetS (14). Susceptibility to MetS transcends
obesity, however, as there are obese individuals
without MetS and nonobese individuals with MetS.
Several factors modulate the prevalence of MetS in the
presence of obesity, including lifestyle factors such as
poor nutritional quality and lack of physical activity.
Age, race, and sex also contribute to metabolic sus-
ceptibility, in part mediated by differences in adipose
tissue distribution and adipocyte size and function.
For example, South Asians have higher body fat con-
tent, waist to hip ratio, visceral fat to subcutaneous fat
ratio, and adipocyte area than Caucasians matched for
age, sex, and body mass index (BMI) (15,16). Similarly,
Filipina women may have higher waist circumference
and truncal fat and 3- to 4-fold higher rates of type 2
diabetes (T2D) and MetS compared with Caucasian
women, controlling for other factors (17).
In the Dallas Heart Study, total body fat correlated
with multiple metabolic risk factors, including insulin
resistance. Excess truncal fat further increased risk
after adjusting for total body fat. Conversely, lower
body subcutaneous fat was protective, and waist
circumference appeared to be a better predictor of
total body fat than BMI (18). Visceral adipose tissue
(VAT) appears to be associated with dyslipidemia and
atherosclerosis, regardless of sex or race (19). Finally,adipocyte size and lack of hyperplasia is associated
with adipose tissue dysfunction, inﬂammatory
markers, and insulin resistance (20,21). Given these
ﬁndings, using a combination of BMI and waist
circumference in MetS risk assessment may prove
better than either measure alone (22). There may also
need to be thresholds for waist circumference and
BMI that differ by race (23).
The challenge presented to the TT was 3-fold. First,
the current deﬁnition of MetS identiﬁes a population
at increased ASCVD risk, but does not accurately
assess that risk, nor does it account for susceptibility
for a given degree of adiposity, as noted earlier.
Second, there is no targeted comprehensive care
approach to address the needs of MetS patients.
Third, assuming there was such an approach, there is
no system to implement risk reduction and disease
prevention. In the sections that follow, each of these
issues is addressed, culminating in the formulation of
afﬁrmed concepts, emergent concepts, and key ﬁnd-
ings relevant to MetS care.
METHODS
The Cardiometabolic TT was convened on June 20,
2014, in Washington, DC, at the American College of
Cardiology (ACC) Heart House as a “call to action”
activity focused on deﬁning new patient care models
and approaches to address contemporary issues of
cardiometabolic risk and disease. The purpose of this
event was for stakeholders to discuss how to best
coordinate care for patients with cardiometabolic risk
factors and MetS. Findings from the PINNACLE reg-
istry (24) prompted ACC leadership to initiate the
TT concept and approach its partners in the Cardio-
Metabolic Health Alliance (CMHA) to participate in
the discussion. The CMHA includes 4 organizations:
the ACC, the American Association of Clinical Endo-
crinologists (AACE), the Association of Black Cardi-
ologists, and the National Minority Quality Forum,
with a mission to improve cardiometabolic risk factor
control in diverse and high-risk populations and
provide more effective coordinated care for patients
with established cardiometabolic disease. CMHA
leadership identiﬁed and extended invitations to
individual experts and representatives of other
organizations beyond the core CMHA members; all
participants are listed in Table 1.
The goal of the TT was to establish and organize
an evidence base to address the following 3 key
questions:
1. What is MetS?
2. What is the optimal care model for patients with
MetS?
TABLE 1 Cardiometabolic Think Tank Representatives and Participant Organizations
Laurence S. Sperling, MD, Co-Chair American College of Cardiology
American Society for Preventive Cardiology
Jeffrey I. Mechanick, MD, Co-Chair American Association of Clinical Endocrinologists
Maria Rosario G. Araneta, PhD National Minority Quality Forum
Quie K. Blum, PhD, NP American Association of Nurse Practitioners
Eliot A. Brinton, MD American Heart Association
Karen K. Collins, MS, RDN, CDN Academy of Nutrition and Dietetics
Stephen Cook, MD, MPH American Academy of Pediatrics
Jean-Pierre Després, PhD International Chair on Cardiometabolic Risk
Nikhil V. Dhurandhar, PhD The Obesity Society
Dave L. Dixon, PharmD Virginia Commonwealth University School of Pharmacy
Brent M. Egan, MD Care Coordination Institute
Daphne P. Ferdinand, PhD, RN Association of Black Cardiologists
Patient/Community Advocate
Alan D. Forker, MD* American College of Physicians
Scott M. Grundy, MD, PhD Keynote Speaker
Yehuda Handelsman, MD American Association of Clinical Endocrinologists
Lawrence M. Herman, MPA, PA-C American Academy of Physician Assistants
Cynthia J. Herrick, MD American Association of Clinical Endocrinologists
(Fellow Representative)
Scott E. Hessen, MD Health Information and Management Systems Society
Terry A. Jacobson, MD National Lipid Association
Chiadi E. Ndumele, MD, MHS Association of Black Cardiologists
Ian J. Neeland, MD American College of Cardiology
(Fellow Representative)
Russell R. Pate, PhD National Physical Activity Plan Alliance
Gary A. Puckrein, PhD National Minority Quality Forum
Robert E. Ratner, MD American Diabetes Association
Krishnaswami Vijayaraghavan
(Kris Vijay), MBBS, MD, MS
American College of Cardiology
*Dr. Forker was unable to attend the Think Tank, but contributed to this document.
Sperling et al. J A C C V O L . 6 6 , N O . 9 , 2 0 1 5
Proceedings of the CMHA Cardiometabolic Think Tank S E P T E M B E R 1 , 2 0 1 5 : 1 0 5 0 – 6 7
10543. What is the optimal strategy to implement this
model?
To accomplish this, the TT was charged with
formulating a paradigm to create and implement a
new care model of patients with cardiometabolic risk
factors and MetS. CMHA leadership organized the
proceedings around 3 core topics:
1. Deconstructing MetS into its components;
2. Constructing a new care model through an inter-
disciplinary approach; and
3. Implementing a new care model in the real world.
The conference began with introductory remarks
from the TT co-chairs (L.S.S. and J.I.M.) and a key-
note address by Dr. Scott Grundy, followed by 3
discussion sessions organized around the core
topics. Each topic session began with a brief pre-
sentation by the topic co-chairs, followed by general
discussion and debate moderated by the co-chairs.
An effort was made to establish points of consensus
and identify alternative viewpoints and knowledge
gaps requiring additional research. The proceedings
were recorded and transcribed. At the end of theday-long session, the TT was directed to develop a
message patterned around afﬁrmed concepts, emer-
gent concepts, and key ﬁndings to document the
current approach to cardiometabolic care (modeled
after the 2013 AACE/ACE Consensus Conference on
Obesity) (25).
WHAT IS MetS AND WHY DOES IT MATTER?
DEFINITION: SYNDROME VERSUS DISEASE. A uni-
fying deﬁnition is needed to facilitate communication
within the scientiﬁc community and between pro-
viders and patients, and to underscore the impor-
tance of incorporating MetS into a comprehensive
preventive care assessment. There is signiﬁcant het-
erogeneity of expert opinion as to what constitutes
MetS, to what degree it represents a syndrome or a
disease, and whether it has any health-related effects
beyond that of its component disorders (26,27). The
importance of MetS in cardiometabolic risk remains
widely under-recognized, as highlighted by the fact
that several of the most recent professional society
guidelines on heart disease and stroke prevention
give little or no attention to its role in disease pre-
vention (28–31). Furthermore, noncardiovascular
conditions promoted by MetS, such as endocrine,
respiratory, and renal disorders, remain under-
emphasized in clinical practice. Last, the current
approach to MetS diagnosis does not take into ac-
count that a greater number of MetS components
translate to a higher risk for adverse outcomes.
The past 2 decades have seen great debate over
what term most precisely articulates the adverse
cardiovascular and metabolic effects of MetS
(Table 2). In 1988, Reaven noted that hypertension,
insulin resistance, atherogenic dyslipidemia, and
obesity tended to cluster to form a complex syn-
drome, syndrome X, deﬁned by a unifying patho-
physiology leading to multiplicative risk for ASCVD
(32). A decade later, the World Health Organization
introduced the term metabolic syndrome, with a pri-
mary focus on insulin resistance and hyperglycemia,
creating controversy about whether the prime driver
of MetS was insulin resistance or obesity (33). In 1999,
the European Group for the Study of Insulin Resis-
tance (EGIR) modiﬁed the World Health Organization
deﬁnition, replacing it with insulin resistance syn-
drome (34). Later, the NCEP-ATP III report codiﬁed
the term metabolic syndrome, highlighting abdominal
obesity—speciﬁcally increased waist circumference—
and an inﬂammatory/prothrombotic state as major
components of the syndrome (35). Terms for MetS
have continued to evolve, each focused around
varying aspects of its pathophysiology, and have
TABLE 2 Previous Criteria Proposed for Clinical Diagnosis of Metabolic Syndrome
Organization
(Year)
(Ref. #) MetS Deﬁnition
Insulin Resistance
or Hyperglycemia Body Weight Dyslipidemia
Elevated Blood
Pressure Other
WHO (1998) (33) Insulin resistance þ
any other
2 criteria
Impaired glucose
tolerance, impaired
fasting glucose,
or lowered insulin
sensitivity
Men: waist to hip
ratio >0.90
Women: waist to hip
ratio >0.85 and/or
BMI >30 kg/m2
TG $150 mg/dl and/or
HDL-C <35 mg/dl
in men or <39 mg/dl
in women
$140/90 mm Hg Microalbuminuria
EGIR (1999) (34) Insulin resistance þ
any other
2 criteria
Plasma insulin >75th
percentile, impaired
glucose tolerance,
or impaired fasting
glucose (but not
diabetes)
WC $94 cm in men
or $80 cm
in women
TG $150 mg/dl and/or
HDL-C <39 mg/dl
in men or women
$140/90 mm Hg or
on hypertension
therapy
None
ATP III (2001) (35) Any 3 of 5 criteria >110 mg/dl (modiﬁed
in 2004 to
>100 mg/dl), diabetes
WC $102 cm in men
or $88 cm
in women
TG $150 mg/dl,
HDL-C <40 mg/dl
in men or <50 mg/dl
in women
$130/85 mm Hg None
AACE (2003) (36) Insulin resistance þ
any of the
other criteria
Impaired glucose
tolerance or
impaired fasting
glucose (but not
diabetes)
BMI $25 kg/m2 TG $150 mg/dl and
HDL-C <40 mg/dl
in men or <50 mg/dl
in women
$130/85 mm Hg Other features
of insulin
resistance including
family history
of diabetes,
polycystic ovary
syndrome, sedentary
lifestyle, and so on
IDF (2005) (49) Body weight þ
any other
2 criteria
>100 mg/dl, diabetes Increased WC
(population
speciﬁc)
TG $150 mg/dl or
on therapy, HDL-C
<40 mg/dl in men
or <50 mg/dl
in women or
on therapy
$130 mm Hg systolic
or $85 mm Hg
diastolic or on
therapy
None
AHA/NHLBI
(2005) (2)
Any 3 of 5 criteria >100 mg/dl or on therapy WC $102 cm in men
or $88 cm
in women
TG $150 mg/dl or
on therapy,
HDL-C <40 mg/dl
in men or <50 mg/dl
in women or on therapy
$130 mm Hg systolic
or $85 mm Hg
diastolic or on
therapy
None
Adapted from Grundy et al. (2).
AACE ¼ American Association of Clinical Endocrinologists; AHA ¼ American Heart Association; ATP III ¼ National Cholesterol Education Program’s Adult Treatment Panel III; BMI¼ body mass index; EGIR¼
European Group for the Study of Insulin Resistance; HDL-C ¼ high-density lipoprotein cholesterol; IDF ¼ International Diabetes Federation; MetS ¼ metabolic syndrome; NHLBI ¼ National Heart, Lung, and
Blood Institute; TG ¼ triglycerides; WC ¼ waist circumference; WHO ¼ World Health Organization.
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1055included the dysmetabolic syndrome (36), insulin
resistance syndrome (36), and cardiometabolic syn-
drome, originally introduced by the pharmaceutical
industry. The position of others, such as the Inter-
national Chair on Cardiometabolic Risk, has been to
identify excess visceral/ectopic fat as the most pre-
valent form of MetS (37). In 2009, several major
organizations released a statement harmonizing the
criteria for MetS, which is in use today (38). Until
recently, medical billing codes experienced a lack of
uniform terminology as well, with the descriptor
dysmetabolic syndrome X (277.7) chosen to represent a
diagnosis of MetS. The more recent International
Classiﬁcation of Diseases-10 coding terminology,
however, has shifted to the more accepted term,
metabolic syndrome (E88.81).
These deﬁnitions are organized around the con-
cepts that MetS: 1) is a chronic and progressive
pathophysiological state; 2) represents a clustering
of risk factors that form a complex syndrome deﬁnedby a unifying pathophysiology; and 3) is associated
with increased risk for ASCVD, T2D, and other
related disorders. It is imperative to recognize that
MetS is not just a repackaging of its individual
risk components, but, as demonstrated in at least
1 analysis, is a clinical entity associated with an
increased risk of ASCVD or death, even after con-
trolling for its component risk factors (risk ratio:
1.54; 95% conﬁdence interval: 1.32 to 1.79) (39).
Furthermore, MetS incorporates so-called residual
risk markers that associate with cardiovascular and
metabolic disease risk, but are not universally agreed
upon as criteria for MetS diagnosis. These include
elevated levels of apolipoprotein B and small, dense
LDL particles; a prothrombotic and proinﬂammatory
state signiﬁed by high levels of circulating inﬂam-
matory markers, such as C-reactive protein and
ﬁbrinogen; and microalbuminuria (2). It is important
to recognize this construct because it provides
an opportunity to identify and treat residual risk
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1056markers beyond the standard management of estab-
lished risk factors.
Another concept essential to the MetS deﬁnition
is that people with MetS have or are at risk for
multi–end-organ damage. This includes, but is not
limited to, cardiovascular (atherosclerosis and non-
atherosclerosis types), metabolic (e.g., T2D and
dyslipidemia), hormonal (e.g., polycystic ovarian
syndrome), sleep-disordered breathing, certain ma-
lignancies, psychological distress (e.g., depression),
chronic kidney disease, orthopedic/joint diseases,
and nonalcoholic fatty liver disease (NAFLD). Sub-
stantial variability in end-organ consequences
emphasizes a need to identify subtypes of MetS on
the basis of their underlying pathophysiology and
predisposition to adverse consequences, which can
then be targeted for speciﬁc preventive and thera-
peutic management strategies (Figure 1).
FOCUS ON PATHOPHYSIOLOGY. Obes i ty . Recently,
the AACE and the American College of Endocrinology
developed an advanced framework for deﬁning
obesity as a chronic disease characterized by patho-
physiological processes that result in increased
adipose tissue mass and can result in increasedFIGURE 1 Paradigm for Subtyping MetS
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obesity epidemic in the United States (41). The latest
prevalence estimates of MetS in men and women are
35% and 33%, respectively (42). Because forecasts
suggest that over one-half of the U.S. population will
be obese by the year 2030, rates of MetS will almost
certainly increase over the next decade. However,
there is a growing appreciation that obesity per se, as
deﬁned by simple anthropometric measures, such as
BMI or waist circumference, is neither a necessary nor
a sufﬁcient descriptor of MetS and its consequences.
Rather, it appears that risk for MetS varies substan-
tially by distribution of both adipocyte and non-
adipocyte (ectopic) fat, as well as by adipocyte size
and function. Excess intra-abdominal (i.e., visceral)
adipose tissue may be a primary driver of the car-
diometabolic complications of obesity (43), and
ectopic fat may be linked to VAT and may itself play
a key contributory role. An increase in VAT is thought
to reﬂect the relative inability of the subcutaneous
adipose tissue depot to sufﬁciently expand its clear-
ance and storage capacity in response to caloric
excess (44). Defects in adipocyte maturation andrdered
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1057differentiation (21) cause adipocyte dysfunction,
resulting in spillover of excess triglycerides and pro-
motion of ectopic fat deposition in the viscera, liver,
heart, and skeletal muscle. The ensuing milieu of
overactive lipolysis, altered glucose homeostasis,
proinﬂammatory adipocytokine release, and endo-
thelial dysfunction appears to be a primary cause of
the pathophysiological alterations observed in MetS.
The several ectopic fat depots associated with
increased cardiometabolic risk include excess liver,
pericardial and epicardial, retroperitoneal, and in-
tramuscular fat (45). Further evidence for the role of
adipocyte dysfunction in adverse metabolic changes
comes from the lipodystrophies, a group of rare
genetic disorders that result in severe, generalized
loss of adipose tissue. Although obesity and lipodys-
trophy represent 2 extremes of the physiological
spectrum, the underlying mechanisms causing insu-
lin resistance and MetS in both sets of patients may
be similar; speciﬁcally, limited storage capacity in
adipose tissue results in diversion of excess tri-
glycerides to ectopic sites, with adverse metabolic
sequelae (46,47). Notably, ectopic fat-associated car-
diometabolic risk in MetS may be further modulated
by race (e.g., South Asians are predisposed), nutri-
tional factors, and lifestyle behaviors.
Although an increased waist circumference is
central to the current clinical diagnosis of MetS and
identiﬁes individuals at increased risk for athero-
sclerosis (48) and mortality across different levels of
BMI (22), it is an imprecise surrogate for the VAT
phenotype. First, the correlation among BMI, waist
circumference, and VAT is highly variable among
different racial groups, prompting the American
Diabetes Association and the International Diabetes
Federation to deﬁne different cutoffs for abnormal
BMI and waist circumference, respectively, in Asian
populations (49,50). Second, waist circumference
measurement includes both VAT and abdominal
subcutaneous adipose tissue compartments. These
2 depots are anatomically and physiologically
distinct, especially within the obese population, and
are differentially associated with markers of car-
diometabolic risk (19). VAT, but not abdominal sub-
cutaneous fat, has been shown to associate with
incident T2D and pre-T2D (51), incident hypertension
(52), and alterations in left ventricular structure and
function (53), and has also been linked to increased
risk of developing CVD and cancer (54). Therefore,
the TT recognized the central role of ectopic fat
and/or visceral adipose tissue in the pathophysiology
of MetS and endorsed evidence-based strategies
to identify and treat these dangerous fat depots in
individuals with or at risk for MetS.Insul in res i stance . Insulin resistance tracks very
closely with MetS, playing a key role in MetS patho-
genesis and relation to ASCVD risk (55). Although in-
sulin resistance may be associated with impairment
of fasting glucose, insulin resistance itself seems to
worsen in severity across added components of
the syndrome, suggesting an independent associa-
tion with MetS beyond glycemic effects (56) and
strengthening the evidence for a pathogenic role of
insulin resistance. Moreover, insulin resistance has
been associated with atherogenic dyslipidemia,
including elevated levels of triglycerides and low
concentrations of HDL-C (2); prothrombotic and
proinﬂammatory markers, such as plasminogen acti-
vator inhibitor-1, ﬁbrinogen (57), and C-reactive pro-
tein (58); increased sympathetic nerve activity and
sodium retention predisposing to hypertension (59);
androgen excess and polycystic ovarian syndrome
(60); sleep-disordered breathing (60); chronic kidney
disease (61); and some cancers (62,63). It remains
unclear whether the insulin resistance seen in MetS is
a purely independent etiological factor, or mostly a
downstream consequence of ectopic/dysfunctional
adiposity, or a combination of both.
RESIDUAL RISK. TT participants afﬁrmed the con-
cept of residual MetS risk indicators. This concept
recognizes that there are additional markers/factors
not incorporated within the traditional diagnostic
framework of MetS that nonetheless relate to MetS
and are associated with adverse health outcomes.
These may vary by individual or group, may be
modiﬁable or nonmodiﬁable, and may have genetic or
environmental determinants. This is critical because
differences in risk factor burden early in life translate
into marked differences in the risk of adverse health
outcomes later in life (64). One element of this has
been highlighted in the “ticking-clock” hypothesis,
which recognizes the detrimental effects of long-term
exposure to MetS on future development of end-
organ damage. For example, multiple factors that
begin before birth and continue through delivery,
such as low birth weight, small head circumference,
gestational diabetes, and lack of breastfeeding, place
children at risk for MetS in adolescence and adulthood
(65). It is important for practitioners to recognize
these and other social determinants of MetS suscep-
tibility, such as low socioeconomic status and parental
history of MetS; to consider providing “primordial
prevention” (66) when possible; and to move toward
identiﬁcation and treatment of vulnerable families
and communities to improve public health.
LIFESTYLE. The TT recognized lifestyle, referring to
physical activity and nutrition, as being a modiﬁable
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sequences. Many observational studies show an
association between higher levels of physical activity
and lower rates of chronic diseases and increased
longevity (67). Even in the presence of MetS,
increased physical activity is associated with a sub-
stantially lower risk of ASCVD (68). The proposed
mechanisms include beneﬁcial effects on blood
pressure and lipids, key components of MetS (28).
Appropriate nutritional choices can also modify the
risk of cardiometabolic disease. The Strong Heart
Study identiﬁed speciﬁc dietary patterns associated
with improved health outcomes (69). Several dietary
patterns, such as the DASH (Dietary Approaches
to Stop Hypertension) and Mediterranean diets,
may reduce blood pressure, improve lipids, reduce
inﬂammation, and reduce risk for ASCVD (28,70).
Emphasis should be placed on dietary patterns, rather
than speciﬁc macronutrients, given inconclusive
evidence to date for an independent effect of macro-
nutrient composition on outcomes (71). Emerging
from these recent data is the belief that focused
research and improved education on lifestyle inter-
ventions should be prioritized.
DISPARITIES. The TT identiﬁed disparity in care of
patients with MetS to be a critical area for improve-
ment. Disparity can manifest as decreased accessi-
bility to health care and failure to recognize or
appropriately treat at-risk populations. For example,
current guidelines do not recognize racial-speciﬁc
differences in lipid levels between Caucasian and
African-American populations (30). On average,
African-Americans have higher HDL-C and lower tri-
glyceride levels (72). This paradox may translate to
underdiagnosis of MetS in African-Americans using
current diagnostic criteria, which would likely result
in lack of treatment of MetS in this population.
In addition to this and other race-speciﬁc issues,
however, TT participants recognized that well-
intentioned alteration of existing diagnostic criteria
around racial differences could stigmatize minority
populations and lead to undesirable consequences.
Other nonracial, high-risk, under-represented pop-
ulations likely requiring more intensive consideration
include patients with human immunodeﬁciency
virus/acquired immunodeﬁciency syndrome, cancer
survivors, individuals with severe mental illness, and
children with developmental disabilities.
WHAT IS THE OPTIMAL INTERDISCIPLINARY
CARE MODEL FOR PATIENTS WITH MetS?
Deﬁning and deconstructing MetS laid the ground-
work for the TT to begin discussing what they agreedwas an emergent need for a new care model for
patients with or at risk for MetS. Participants identi-
ﬁed several essential considerations in response to
the dynamic health care environment of the 21st
century. These included: focusing on comprehensive
screening/case-ﬁnding strategies; considering vary-
ing MetS phenotypes; formulating a staging system
to facilitate communication between patients and
providers; and building a paradigm of care involving
individual, community, and public/global health that
emphasizes lifestyle choices.
STAGING SYSTEM FOR THE METABOLIC SYNDROME—A
FRAMEWORK. The TT recognized that providers need
a more comprehensive, but simply communicated,
framework through which they can identify and
risk-stratify patients with or at risk for MetS. Such a
framework can be used to apply evidence-based,
targeted therapeutic interventions. By highlighting
the progressive nature of MetS in stages, participants
proceeded to devise a theoretical system with sug-
gested criteria and recommended therapy for each
stage (Figure 2). The system starts by recognizing
persons who are at risk for MetS, but without any of
the 5 criteria required to meet a MetS diagnosis.
Factors to consider at this stage include overweight
(incorporating the recent AACE framework [40]),
evidence for ectopic fat deposition by imaging, racial,
or parental susceptibility to MetS, and adverse life-
style choices. Therapeutic interventions would be
implemented to address speciﬁc health behaviors
or markers of susceptibility to prevent progression
(primary prevention). The model then moves toward
increasingly severe stages of MetS on the basis of
established risk factors/diagnostic criteria and resid-
ual risk markers. Each stage, considered secondary
prevention, proposes more intensive therapeutic
strategies to treat MetS and its risk factors. It should
be noted that although risk for adverse outcomes
generally increases with each subsequent stage, the
absolute risk for developing MetS consequences
varies substantially within populations. Thus, it is
imperative that treatment decisions be incorporated
within the context of absolute risk.
In summary, this model categorizes patients ﬁrst
on the basis of the stage of their disease progression
and second by underlying MetS pathophysiology. The
strengths of this model are that it: 1) recognizes the
heterogeneity of MetS and the need for individual-
ized care strategies; 2) highlights the importance of
disease-speciﬁc pathophysiology in the evolution of
MetS; 3) acknowledges that many patients with MetS
have overlapping subtypes requiring a multidisci-
plinary approach to their care; and 4) maps MetS
stages with speciﬁc management strategies. The TT
FIGURE 2 Stages in the Evolution of MetS and Recommended Therapy by Stage
Absolute Risk for End-Organ Damage
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This staging system highlights the progressive nature of MetS, with suggested criteria and recommended therapy for each stage. All thera-
peutic decisions should be made within the context of absolute risk for end-organ damage. Alt ¼ alternative; BP ¼ blood pressure; CKD ¼
chronic kidney disease; CVD ¼ cardiovascular disease; HDL-C ¼ high-density lipoprotein cholesterol; MetS ¼ metabolic syndrome; NAFLD ¼
nonalcoholic fatty liver disease; OSA ¼ obstructive sleep apnea; TG ¼ triglycerides; WC ¼ waist circumference.
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1059acknowledges that the concepts of staging and sub-
typing are works in progress and require further
modiﬁcation, testing, and validation before they can
be used routinely in clinical care.
BUILDING A NEW CARE PARADIGM: THE INTEGRATED
CARE MODEL. The TT agreed that care for patients with
MetS should focus on disease prevention and man-
agement within a continuum of individual, commu-
nity, and public/global health (Central Illustration).
Focusing on prevention requires more comprehensive
screening for MetS in the community. Some examples
include opportunities to screen families at well-child
pediatric or pharmacy visits; using electronic medical
records to improve screening/case ﬁnding; and
expanding screening efforts to schools, worksites,
places of worship, and community businesses.
Screening should use measurable biomarkers (e.g.,
blood pressure, lipids, BMI, and waist circumference),
as well as better assess and target behaviors, such as
physical inactivity and nutritional quality. Taking
advantage of emerging technologies (e.g., wearable
devices) should be further explored to enhance
screening. Community engagement strategies canaugment screening by increasing awareness of MetS
and promoting healthy behaviors. These include
making healthy eating and regular physical activity
accessible, affordable, and acceptable. One successful
example of this approach is the community-based
practice network, where community leaders partner
with health care practices to create public health
awareness, with real-time feedback and data analysis
for quality improvement (73). This approach can be
improved by increasing patient access to ancillary
services using ZIP code analysis to focus resources on
high-risk areas (74) and using public health and com-
munity initiatives. By engaging the community more
broadly, the focus can begin to shift from the indivi-
dual to larger units (families, communities, neighbor-
hoods, and populations), which will increase the
effectiveness of screening and start to change the
culture of care.
Second, participants felt that better metrics are
needed to deﬁne abdominal obesity, as current deﬁni-
tions are imprecise and not well suited for many pop-
ulations. As technology develops and the critical role
of ectopic fat and/or visceral adipose tissue continues
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Care for patients with MetS should be focused on prevention and disease management within a continuum of individual, community, and public/global
health. MetS ¼ metabolic syndrome.
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1060to emerge, metrics should evolve to consider alterna-
tive methods of measuring obesity. Simpler and less
expensive methods than computed tomography and
cardiac magnetic resonance imaging to measure fat
distribution are needed to better characterize car-
diometabolic risk. In the interim, other potentiallymodifying factors should be taken into account,
including race susceptibility, lifestyle, and evidence
for metabolic dysfunction beyond the speciﬁc MetS
criteria, such as NAFLD or sleep-disordered breathing.
Finally, with the advent of the PCMH and ACOs,
care of patients with or at risk for MetS will likely
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interdisciplinary care and greater involvement of
family and community resources. The vision of the TT
was to integrate care across general practitioners and
specialists, in addition to ancillary resources, with a
patient-centered and culturally sensitive approach.
This will create a virtually integrated network of care
providers sharing information with real-time data
gathering and quality improvement to help patients
reach their goals. For example, the ACO Shared Savings
Program has reported substantial improvements in
blood pressure screening (76%), achieving glycosy-
lated hemoglobin (HbA1c) <8% (69%), LDL cholesterol
<100mg/dl (55%), and aspirin use (75%) in participants
with T2D compared with current NHANES reports for
the general population with T2D (75).
Integrated health networks allow patients to
monitor their own progress, which improves self-
motivation and patient engagement in self-care. The
TT recognized several key issues required to achieve
this goal. First, time constraints placed on clinicians
necessitate more robust and focused training to
address health promotion during brief patient-
provider encounters. Second, funding should extend
beyond covering end-organ consequences to include
covering those at risk for MetS. Payers and employer-
based insurers must see MetS as a priority. Increased
emphasis on MetS staging paradigms should help
demonstrate that early intervention prevents more
costly end-organ consequences. Finally, there is a
need for more data/evidence for MetS care within
diverse populations. One example is the new Diabetes
Collaborative Registry (76), housed in the ACC and
linked to the PINNACLE registry, which will facilitate
crosstalk between registries and improve research. As
health care evolves to become more prevention-
focused, a new care model for patients with MetS
should continue to encourage high-intensity lifestyle
interventions to reduce morbidity and mortality from
MetS and its consequences (31,77).
WHAT IS THE OPTIMAL STRATEGY
FOR IMPLEMENTING A NEW CARE MODEL
FOR MetS?
The ﬁnal challenge for TT participants was imple-
mentation of a new care model for MetS. Clear
consensus was that stakeholders from the community
and public health arena, the health care system, and
industry must be involved and that patient advo-
cates, community health workers, and peer leaders
are essential to bridging the community and the
health care system. Stakeholders include physicians,
nurse practitioners, and physician assistants, as wellas ancillary health professionals such as dietitians,
exercise physiologists, psychologists, behavioral
specialists, and certiﬁed diabetes educators. Disci-
plines to be involved include family practice, pedi-
atrics, internal medicine, obstetrics and gynecology,
geriatrics, and specialists in cardiology (hypertension
and lipid) and endocrinology (diabetes and obesity).
Other medical specialties that may also be involved
with this population presenting with a particular
phenotype include gastroenterology (NAFLD), sleep
medicine (obstructive sleep apnea), nephrology (car-
diorenal syndrome), surgery (bariatric, vascular, and
cardiothoracic), psychiatry (depression, other behav-
ioral), and oncology (obesity-associated malig-
nancies). Finally, industry is another key stakeholder,
as pharmaceuticals and surgical interventions com-
prise important treatment options for patients with
MetS. It is important to note that many of the pro-
visions of the Affordable Care Act (ACA) would sup-
port this implementation.
Dissemination of the Diabetes Prevention Program
(DPP) in community settings can serve as a model
for the MetS population. The DEPLOY (Diabetes Ed-
ucation & Prevention with a Lifestyle Intervention
Offered at the YMCA) study was a pilot cluster-
randomized trial comparing group-based DPP life-
style intervention through a Young Men’s Christian
Association (16 group sessions with goals of 5% to
7% reduction in baseline body weight and 150 min/
week of moderate exercise) with brief counseling.
Among 92 randomized participants, at both 4 to 6
and 12 to 14 months, the percent change in weight
and BMI, as well as the change in total cholesterol,
was signiﬁcantly greater in the intervention group
(78). An extension study in which both the control
and intervention arms were offered an 8-month
lifestyle maintenance program found that both
groups maintained weight changes compared with
baseline, and those in the initial intervention group
lost a further 1.5% of body weight, with signiﬁcant
decreases in total cholesterol and systolic blood
pressure (79). A larger implementation of the DPP
intervention across 14 Young Men’s Christian Asso-
ciations in New York demonstrated that among 254
participants, 40.2% and 60.8% achieved a weight
loss $5% at 16 weeks and 10 months, respectively
(80). Lessons could be drawn from these in-
terventions to beneﬁt other communities, such as
the workplace, where many large employers already
offer wellness programs. A systematic review of
randomized controlled trials on worksite wellness
programs demonstrated a statistically signiﬁcant 3-lb
weight reduction and 0.5 kg/m2 BMI reduction over
6 to 12 months (81).
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Activity Plan as an overarching framework for
implementation. The plan has 5 primary strategies
and proposes evidence-based interventions within 8
economic sectors. Strategies include launching
advocacy efforts to increase public support, mounting
a national physical activity education program,
disseminating best practice models, creating a na-
tional resource center, and establishing a center for
physical activity policy development and research.
Involved sectors include: business and industry;
education; health care; mass media; parks, recrea-
tion, ﬁtness, and sports; public health; transpor-
tation; land use; community design; volunteer; and
nonproﬁt. Speciﬁc strategies within these sectors
include providing incentives to increase active
transportation (walking, biking) through community
design, making physical activity a “vital sign” in the
health care setting, and ensuring access to high-
quality physical activity programs in early childhood
education and grade school (82).
The TT proposed that community health workers
and peer leaders play an integral role in implement-
ing the new care model and discussed several exam-
ples. The Healthy Living Partnerships to Prevent
Diabetes Study implemented a DPP-like lifestyle
weight-loss program over 2 years by using a local
diabetes education program with community health
workers, involving weekly visits over the ﬁrst
6 months and twice monthly visits over the next
18 months (83). Among 301 randomized patients, the
intervention group achieved signiﬁcant reductions in
weight, BMI, waist circumference, glucose, insulin,
and homeostatic model assessment of insulin resis-
tance measures compared with control subjects, with
46.5% of the intervention group achieving $5%
weight loss and 21.3% achieving $10 % weight loss
(83). The Look AHEAD (Action for Health in Diabetes)
trial provides the longest-term evidence of the effect
of an intensive lifestyle intervention in overweight
and obese adults with T2D. The curriculum was
modiﬁed from the DPP and included structured meal
plans and moderate exercise up to 200 min/week. At
8 years, 50.3% in the intervention group versus 35.7%
in the usual care group lost $5% of body weight, and
26.9% versus 17.2% lost $10% of body weight (84).
In Colorado Heart Healthy Solutions, community
health workers conducted screenings, assessed read-
iness for change, and provided education and medical
referrals to patients with an uncontrolled risk factor
for coronary heart disease or a Framingham Risk
Score $10%. They provided further phone follow-up,
and found signiﬁcant reductions in Framingham Risk
score, blood pressure, and cholesterol at retesting. Inmultivariable models, those receiving a follow-up call
had greater improvement in Framingham Risk Score
than those who did not (85). A randomized controlled
trial in 2 community health centers enrolled 525 pa-
tients with uncontrolled ASCVD, T2D, hypertension,
or hyperlipidemia; results showed that pairing nurse
practitioners and community health workers dem-
onstrated signiﬁcant reductions in blood pressure,
cholesterol, and HbA1c over 1 year of follow-up
compared with usual care (86). Finally, peer leaders
can effectively provide education and support for
lifestyle. This was demonstrated in a study where 116
Latino adults with T2D were randomized to receive
diabetes self-management education and either
12 months of weekly group sessions with peer leaders
or 12 months of telephone outreach with health
workers (87). Both groups achieved signiﬁcant HbA1c,
blood pressure, and waist circumference reductions
and improved diabetes support with less distress.
However, only the peer leader group sustained HbA1c
and blood pressure reductions over 18 months (87).
To further highlight lifestyle change, the TT pro-
posed campaigns such as the Exercise is Medicine
initiative (88), which assesses patient readiness for
exercise and provides handouts to help patients start
a program. It also provides materials to help ﬁtness
professionals communicate with health care per-
sonnel. To emphasize the importance of addressing
disparities, the TT discussed key studies such as the
Lawrence Latino Diabetes Prevention project (89),
which recruited 312 participants at high risk for T2D
for a lifestyle intervention involving 3 individual and
13 group sessions over 12 months versus usual care.
The curriculum was adapted to address knowledge
gaps and language barriers, customize dietary advice
to Latino cuisine, and use the popular novella media
format to deliver messages. At 1 year, there was a
signiﬁcant reduction in weight, BMI, and HbA1c in the
intervention group as compared with usual care (89).
Another cultural adaptation of the DPP in African-
American churches involved 37 participants and
compared an abbreviated 6-week program to a longer
16-week program; it found that fasting glucose and
BMI decreased signiﬁcantly in both groups at
12 months (90). A program targeting a predominantly
low-income non-Caucasian urban population deliv-
ered a lifestyle intervention in 12 weeks using group
sessions and found signiﬁcant reductions in the pro-
portion of subjects meeting the MetS waist circum-
ference (90% to 68%; p ¼ 0.009) and hypertension
(68% to 48%; p ¼ 0.04) criteria over 6 months. At 3
months, 46.4% lost $5% of body weight and 26%
lost $7% of body weight, with 87.5% and 66.7% sus-
taining these losses at 6 months, respectively (91).
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1063Araneta et al. (92) piloted a 12-week Zumba ﬁtness
program in sedentary obese women with $2 MetS
criteria (77% ethnic minorities), demonstrating sig-
niﬁcant blood pressure and fasting triglyceride re-
ductions among the participants. The investigators
also conducted a 48-week randomized controlled trial
comparing restorative yoga to active stretching
among adults with MetS, ﬁnding signiﬁcantly lower
fasting glucose in the yoga group at 12 months (93).
Principles for implementing a new care model
within the health care system should include: care
coordination and team-based care; education in MetS
recognition and treatment; technology to facilitate
communication among providers and patients; dis-
ease registries for population management; social
media for distributing health messages; reimburse-
ment alignment to facilitate coordinated care; and
further development of strategies to address health
care disparities and barriers to care. The TT recog-
nized that the ACA supports 2 emerging models that
seek to address these issues and improve integrated
care for complex patients.
PATIENT-CENTERED MEDICAL HOME. To varying
degrees, the PCMH addresses each of the aforemen-
tioned principles of care model implementation. The
PCMH is organized around several core principles:
1) comprehensive team-based care; 2) patient-
centered care; 3) care coordination; 4) accessible ser-
vices; and 5) quality improvement and safety (94). A
systematic review of 31 studies found a positive effect
of components of the PCMH model on patient and
staff experiences, as well as positive effects on pre-
ventive services, with reduction in emergency
department visits in older adults, but no effect on
hospital admissions or total costs (95). However,
comparisons across studies on the PCMH are often
difﬁcult because of differences in deﬁnition and focus.
In another study of 36 family practices implementing
PCMH components over 26 months, improvement
was seen in prevention and chronic care quality
metrics, but not in patient-assessed outcomes (96).
Long-term data is also limited, as most of these
models were implemented over the last 5 to 10 years.
The Group Health Cooperative reduced physician
panel sizes, increased ancillary staff, lengthened
visit times, and provided time for team care planning,
in addition to expanding technology to better engage
patients. Comparison with control clinics in the
area demonstrated better patient satisfaction scores,
reduced provider burnout, improved performance
on quality of care metrics, and reduced emergency
department visits and inpatient admissions for
ambulatory sensitive conditions over a 12- to 24-month follow-up (97). The PCMH model affects MetS
sequelae and outcomes. For example, the Geisinger
ProvenHealth Navigator demonstrated a reduction in
the incidence of end-stage renal disease and amputa-
tion among patients with T2D over 4 years, although
without a change in myocardial infarction or stroke
(98). Evaluation of another such model in West Vir-
ginia found that an EHR-based screening tool identi-
ﬁed 11% of over 94,000 patients as being at risk for T2D
(99), enabling the facility to better screen and connect
patients to local lifestyle intervention programs.
There is less published data available to assess
PCMH reimbursement strategies to facilitate coordi-
nated care or on how this model addresses health care
disparities. Although different ﬁnancial models have
been proposed and are incorporated in some PCMH
models, evaluations do not speciﬁcally address the
effectiveness of these strategies, nor have most
studies demonstrated overall short-term cost savings
(100). A recent review of 27 PCMH studies found that
only 11 provided any detail on their ﬁnancial models
(101). There is also a limited evidence base for
addressing disparities. In fact, in a retrospective
cohort study of 1,457 diabetic patients receiving care
in a PCMH academic practice, African-American pa-
tients were less likely to receive HbA1c testing or
inﬂuenza vaccination or to meet LDL or blood pres-
sure targets than non-Hispanic Caucasians, after
adjusting for multiple demographic factors and com-
orbidities (102). Similar to the cultural adaptations of
the community-level interventions discussed earlier,
new PCMH models must be modiﬁed to speciﬁcally
address the needs of particular populations.
ACCOUNTABLE CARE ORGANIZATIONS. The ACO is
another mechanism relevant to implementing a new
MetS care model. Although the PCMH focuses on
coordination at the level of primary care, the ACO is a
larger organization that includes hospitals and spe-
cialty care. Compared with many PCMH models, the
ACO’s reimbursement changes and cost-saving goals
are more explicit and are better aligned to facilitate
coordinated care. Most ACO models are very new,
but available evaluations indicate that health care
spending has declined. Medicare beneﬁciaries in the
same market as a commercial ACO realized decreases
in total health care spending over 2 years, primarily due
to reduced outpatient ofﬁce visits, minor procedures,
imaging, and laboratories. There were some improve-
ments in LDL testing for patients with T2D and ASCVD
but not on other quality metrics (103). An evaluation of
Medicare enrollees in the Medicare Physician Group
Practice Demonstration compared with control sub-
jects found that the savings were highest for acute
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1064care and dually-eligible beneﬁciaries, with an overall
reduction in 30-day medical readmissions (104). Ac-
cording to a Centers for Medicare & Medicaid Services
release of 1-year data, ACOs have also slowed cost
growth (0.3% vs. 0.8% in 2012), reduced readmission
rates, improved blood pressure control, and better
assessed LDL in patients with T2D (105).
In addition to cost savings, ACOs have successfully
implemented quality improvement initiatives, as
demonstrated by 1 evaluation in 11 primary care
clinics that employed care coordination, a care gap
summary tool, staff education, and workﬂow redesign
(106). Although integration of care into larger orga-
nizations may address health care disparities, this has
not been speciﬁcally addressed in ACO design. An
evaluation examining differences in care provided to
Caucasian and African-American Medicare beneﬁ-
ciaries according to size of provider group found that
beneﬁciaries assigned to larger groups were more
likely to be Caucasian with lower poverty rates and
higher educational attainment compared with those
in small or medium groups. African-American bene-
ﬁciaries with T2D were less likely to receive LDL
testing and retinal examinations and were more likely
to be hospitalized than Caucasian beneﬁciaries.
Although larger provider groups attenuated racial
disparities in some areas, they did not change dis-
parities on other metrics, such as hospitalization rates
(107). ACOs will need to speciﬁcally address health
care disparities among patients with MetS.
CONCLUSIONS AND FUTURE DIRECTIONS
Several important challenges remain in the care of
patients with MetS. These include collecting more
data and developing expert consensus on MetSdiagnostic subtyping and staging to improve risk
stratiﬁcation and personalized medical care. Future
TT initiatives will provide objective data on the
combined use of pharmaceuticals, structured life-
style, behavioral interventions, and surgical/non-
surgical bariatric procedures to improve morbidity
and mortality among patients with or at risk for
MetS. A greater emphasis on assessing nutritional
quality and levels of physical activity, with a focus
on ﬁlling the gap between public health approaches
and implementation in clinical practice, will be
needed. Care models will continue to incorporate
ACOs, but uncertainty exists as to how the ACA will
affect MetS care in the future. It is foreseen that
health care will transition to a greater degree from
the clinic to the community, improving access to
care, and that there will be a broadening of stake-
holders to include public health, community, and
industry sectors. Screening and performance metrics
will enhance implementation of new care models in
the future. Finally, the TT afﬁrmed a call to action to
encourage ongoing partnerships, funding, and ini-
tiatives to improve the lives of people with or at risk
for MetS.
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